GHENT, Belgium, 15 February 2012 - Ablynx [Euronext Brussels: ABLX] plans to announce its full year results for 2011 on 22 February 2012 after market closure.

Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference call webcast during which the full year results for 2011 will be presented, followed by a Q&A session. This event will be held on Thursday, 23 February 2012 at 4.00 p.m. CET.

The conference call will be webcast live and may be accessed on the home page of the Ablynx website at www.ablynx.com. Shortly thereafter, a replay of the webcast will be available on the Company's website.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies^®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com